Biomarkers Development

The development of cancer therapies is increasingly dependent on our understanding of tumor biology, and biomarkers—especially predictive biomarkers—are crucial tools in the field of personalized medicine and health economics, in particular, as they enable definition of the populations of patients who are most likely to benefit from targeted therapies. More-effective patient selection than is possible at present is mandatory to improve the success rate of new therapies, which are sometimes prohibitively expensive, and thereby increase their cost–utility; thus, delineating reliable predictive biomarkers is essential if we are to achieve this objective. One commonly used definition of a biomarker is a measurable indicator that is used to distinguish precisely, reproducibly and objectively either a normal biological state from a pathological state, or the response to a specific therapeutic intervention. In fact, biomarkers are used for numerous purposes: to predict survival (prognostic biomarkers); to assess drug safety and evaluate target engagement and the immediate consequence on biological processes (pharmacodynamics biomarkers), to identify patients who are more likely to benefit from a treatment (predictive biomarkers; more generally termed companion biomarkers when associated with a specific therapeutic agent); to predict outcome given the response to therapy (surrogate biomarkers); and to monitor disease progression or therapeutic efficacy (monitoring biomarkers). Identification and widespread use of biomarkers will help ensure that patients receive the best possible therapeutic strategies, thereby avoiding unnecessary treatments and associated toxicities, and eventually reducing total health costs.

Even though immunotherapeutic approaches are being studied in many cancer types, correlative studies have thus far been most extensively conducted in melanoma, providing valuable experience and making it a model system for identifying therapeutic biomarkers.

  • Turning an Active Compound into a Personalized Medicine
  • Evaluation of Biomarker Performance in the Real World
  • Predicting Benefit to Therapy: Biomarkers and Molecular Profiles in Oncology Drug Development
  • Identification of Fluid Biomarkers of Treatment
  • Surrogate endpoints: utilising biomarkers in clinical trials

Related Conference of Biomarkers Development

May 16-17, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan
September 13-14, 2018

World Conference on Vaccine and Immunology

Bucharest, Romania
September 13-14, 2018

11th Annual Congress on Immunology & Immunotechnology

Zurich, Switzerland
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 20-21, 2018

Global Meet on Immunology and Molecular Biology

Oslo, Norway
October 19-20, 2018

10th World Congress and Expo on Immunology

New York, USA
October 29-30, 2018

6th International Conference on HIV/AIDS, STDs and STIs

San Francisco, USA
November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland
December 06-07, 2018

Annual Congress and Expo on Antibiotics

Amsterdam, Netherlands
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain

Biomarkers Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in